Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lots of pending FDA decisions that need to be made for Elite. Lots.
Site transfer approvals for:
Isradipine
Dantrolene Sodium
Loxapine
Hydroxyzine
and eight others
Then there are two "undisclosed generics" ANDA's that have been pending FDA approval for some time now.
Lasers.
Elite isn't the first co. to develop micro-tablets of course.
I am not sure what it is about this patent that makes it unique/better and therefore patent-able.
Have you had a chance to analyze it and determine the key differentiators and/or "value adds"?
Thanks in advance.
I'm not sure I understand what you are saying here?
Yes
Pipeline chart
Look at pipelines for IPCI, TNXP and ADMP for example
Dianne would never say that ...
Thanks!
And about 1000% gain since 2011 ....get over it
This was .37 last week. Now its 0.4397
How exactly is that "tanking"?
That's a gain of 18.8% in 7 days.
Pipeline updated again:
http://www.changedetection.com/log/elitepharma/product_pipeline_log.html
OK, I'll give us something to talk about before the next CC.
I'm NOT predicting... but lets say I am laying out what I think is possible.
Given my already infinite return on investment I am hoping for infinity and beyond!
Isradipine approval by end of JUNE gets us to .40
Continued revenue growth revealed in LATE JUNE 10K and CC gets us to .42 by July
I think positive liability studies gets us back to .50 by end AUGUST.
Dantrolene Sodium & Loxapine approval by mid October gets us to .55
Filing of 1st ART w/ FDA plus a "surprise" announcement (marketing partner?, fast track grant for first ART?) gets us to .75 by December 1st.
Approval of additional "Mikah" generics will get us to $.85 by December 31st.
Filing of second and possibly third ART drug w/ FDA by 3/31/15 gets us to $1.25
Approval of first ART drug by FDA gets us to $1.70 by 12/31/15.
Announcement of 1st shipments of 1st ART drug gets us to $1.90 by 1/15/16.
Elite announces FDA approval for two more ART drugs by 6/30/16 - PPS to $2.25
Elite announces first $30,000,000 quarter on 7/15/16, PPS to $2.50
Elite announces reverse 2 to 1 split and NASDAQ uplisting. PPS to ?
Nasrat at the shareholders meeting referenced 17 ART products
Meaning earnings could be Thursday/Friday, 6/26 or 6/27?
Purdue Pharma completed a late-stage trial of its extended-release--and abuse-deterrent--formulation of hydrocodone bitartrate earlier this year and filed for FDA approval on April 30. Observers say that, if Purdue is successful, the FDA could force Zogenix to pull Zohydro, which doesn't include tamper-resistant features.
Read more: Chicago sues J&J, Purdue, Endo, Actavis, Teva over opioid marketing - FiercePharma http://www.fiercepharma.com/story/chicago-sues-jj-purdue-endo-actavis-teva-over-opioid-marketing/2014-06-03#ixzz34RlD4VcB
Subscribe at FiercePharma
I only posted a link since others asked for one.
I pass no judgement on it. I just had 10 seconds to Google it.
I have many investor friends that believe in this.
I have not had the time to dig into it. But I'm doing my DD as time allows.
Lasers, what do you think is holding up a PR on this?
Elite generally PR's upon "first shipment" correct?
So could it be they are in the midst of manufacturing and packaging their first shipment?
Me too!
Thanks.
It was my intention to start with what I thought were conservative assumptions. Helps me sleep a little better!
This is a projection based on the indicated assumptions in the spreadsheet.
What do you think the share price would be if IPCI achieved $138,000,000 in annual revenue without further dilution?
What do you think of the assumptions?
I don't profess to "know" what the share price will be. I am trying to build a rudimentary model to project share price based on their pipeline.
I was hoping a mature constructive dialogue could take place here to point out flaws in assumptions and make improvements.
What makes you say that?
Just fooling around with numbers/projections...
Any thoughts??
https://www.dropbox.com/s/zbtxdxjd2lvzkhl/Screenshot%202014-06-09%2011.47.24.png
I am inclined to believe its targeted at Embeda also.
Just don't want to leave out other possibilities.
But the branded drug doesn't necessarily have to be an ADT drug.
It could be Opana, Exalgo whatever.
Lasers.
How do we know ELI200 is Morphine/Naltrexone?
cause you said so? oh, golly...
How do we know they haven't started liability studies?
Maybe they are waiting til they are completed?
Seems to me most folks are sitting on their shares and not selling.
Those that may be interested in buying are waiting for the slow decline on very low volume to bottom out before jumping in.
Once it hits that level and starts trending back up it could move in a hurry.
What is AMMX net take on this contract?
"We feel very strongly that the current technologies available are not adequate to truly turn the tide on the epidemic of abuse, and we need continuing advancement in the field of abuse-deterrent technology," The FDA's Hamburg said.
"We feel very strongly that the current technologies available are not adequate to truly turn the tide on the epidemic of abuse, and we need continuing advancement in the field of abuse-deterrent technology," The FDA's Hamburg said.
"We feel very strongly that the current technologies available are not adequate to truly turn the tide on the epidemic of abuse, and we need continuing advancement in the field of abuse-deterrent technology," The FDA's Hamburg said.
That too!
Approximately 6/23
Another day closer to Isradipine launch, Liability studies, and ART NDA filings...
In your opinion
When did Elite claim they did not need efficacy data? Please provide some substantiation for this claim.